IP Library Granted Patent US 8,980,247
Granted Patent B2
US 8,980,247 · App. 13/324,484 · Granted Mar 17, 2015

Parvovirus methods and compositions for killing neoplastic cells

Inventors: Craig M. Meyers (Hummelstown, PA); Samina Alam (Hershey, PA)
Assignee: The Penn State Research Foundation
A61K35/768C12N7/00C12N2750/14132C12N2750/14133A61K38/00C07K14/005C12N2750/14122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,247
App. No.
13/324,484
Granted
Mar 17, 2015
Kind
B2
Abstract

According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursors, while leaving healthy cells intact. The invention also includes a method of killing cancer and other neoplastic and preneoplastic cells by administrating to said cells the AAV2 proteins Rep78 or Rep 68, expression constucts encoding the same, or pharmaceutical compositions comprising the same.

Claims (10)

1. A method of treating or ameliorating cancer comprising administering to a patient having cancer, a recombinant protein comprising AAV2 Rep68 and AAV2 Rep78, and

inducing an increase in S-phase entry in cancer cells in said patient,

wherein said treatment or amelioration of said cancer is performed without inclusion of any additional anti-cancer compound, chemotherapeutic agent, or other DNA damaging agent.

2. The method of claim 1 wherein said protein is administration is by administration of an expression construct comprising a nucleic acid sequence which encodes an AAV2 Rep 68 and Rep 78 protein.

3. The method of claim 1 wherein said protein has an amino acid sequence of SEQ ID NO:2 and 4.

4. The method of claim 2 wherein said nucleic acid sequence encodes the protein of SEQ ID NO:2 and 4.

5. The method of claim 4 wherein said nucleic acid sequence includes the sequence of SEQ ID NO:1 and 3 operable linked to a promoter sequence.

6. The method of claim 1 wherein said protein induces apoptosis.

7. The method of claim 1 wherein said protein is administered as part of a genetically modified AAV2 virus.

8. The method of claim 1 wherein said cancer is breast cancer, cervical, mesothelioma, prostate cancer, squamous cell carcinoma or melanoma.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 15, 2012
From: THE PENNSYLVANIA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028382/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2012
From: MEYERS, CRAIG M.; ALAM, SAMINA
To: THE PENN STATE RESEARCH FOUNDATION
Reel/Frame 028187/0021 →
Continuity (3)
Continuation In Part 11577782
Provisional Application 60620928 · Oct 21, 2004
Related Publication 20120213736A1 · Aug 23, 2012